Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com

Posted by on Jul 17th, 2023

Equities researchers at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a report released on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Aeterna Zentaris in a report on Friday.

Aeterna Zentaris Stock Performance

Shares of Aeterna Zentaris stock opened at $2.87 on Monday. Aeterna Zentaris has a 52-week low of $2.32 and a 52-week high of $5.95. The stock has a market capitalization of $13.95 million, a price-to-earnings ratio of -0.57 and a beta of 1.30. The company’s 50 day moving average price is $2.83 and its 200-day moving average price is $3.07.

Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.19. The company had revenue of $2.13 million during the quarter, compared to the consensus estimate of $0.90 million. As a group, equities research analysts forecast that Aeterna Zentaris will post -3.41 earnings per share for the current fiscal year.

About Aeterna Zentaris

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.